| Primary |
| Renal Transplant |
23.9% |
| Immunosuppression |
20.5% |
| Prophylaxis Against Transplant Rejection |
10.8% |
| Drug Use For Unknown Indication |
7.4% |
| Product Used For Unknown Indication |
6.1% |
| Lupus Nephritis |
4.3% |
| Immunosuppressant Drug Therapy |
4.1% |
| Liver Transplant |
4.1% |
| Systemic Lupus Erythematosus |
3.3% |
| Prophylaxis |
2.9% |
| Hypertension |
2.3% |
| Prophylaxis Against Graft Versus Host Disease |
1.7% |
| Infection Prophylaxis |
1.4% |
| Heart Transplant |
1.2% |
| Graft Versus Host Disease |
1.1% |
| Transplant |
1.1% |
| Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis |
1.0% |
| Stem Cell Transplant |
1.0% |
| Transplant Rejection |
0.9% |
| Prophylaxis Against Renal Transplant Rejection |
0.9% |
|
| Death |
20.5% |
| Transplant Rejection |
17.9% |
| Urinary Tract Infection |
6.3% |
| Sepsis |
5.6% |
| Weight Decreased |
4.5% |
| Vomiting |
4.1% |
| Renal Failure |
4.0% |
| Pneumonia |
3.9% |
| Pyrexia |
3.4% |
| Renal Failure Acute |
3.4% |
| Kidney Transplant Rejection |
3.2% |
| Respiratory Failure |
2.8% |
| Septic Shock |
2.8% |
| Renal Impairment |
2.7% |
| Neutrophil Pelger-huet Anomaly Present |
2.6% |
| Bronchiectasis |
2.5% |
| Diarrhoea |
2.5% |
| Systemic Lupus Erythematosus |
2.4% |
| Colitis |
2.3% |
| Thrombocytopenia |
2.3% |
|
| Secondary |
| Renal Transplant |
22.1% |
| Prophylaxis Against Transplant Rejection |
14.1% |
| Immunosuppression |
10.1% |
| Prophylaxis Against Renal Transplant Rejection |
7.7% |
| Prophylaxis |
6.4% |
| Product Used For Unknown Indication |
6.3% |
| Drug Use For Unknown Indication |
3.5% |
| Liver Transplant |
3.4% |
| Infection Prophylaxis |
3.3% |
| Heart Transplant |
3.3% |
| Immunosuppressant Drug Therapy |
3.2% |
| Prophylaxis Against Graft Versus Host Disease |
3.0% |
| Hypertension |
3.0% |
| Lupus Nephritis |
1.9% |
| Stem Cell Transplant |
1.8% |
| Systemic Lupus Erythematosus |
1.6% |
| Thrombosis Prophylaxis |
1.6% |
| Lung Transplant |
1.4% |
| Antifungal Prophylaxis |
1.3% |
| Graft Versus Host Disease |
1.2% |
|
| Urinary Tract Infection |
14.4% |
| Transplant Rejection |
10.0% |
| Vomiting |
7.5% |
| Sepsis |
7.2% |
| Ureteric Stenosis |
6.6% |
| Pyrexia |
6.2% |
| Urosepsis |
4.8% |
| Pneumonia |
4.4% |
| Cytomegalovirus Infection |
4.1% |
| Renal Impairment |
4.1% |
| Thrombocytopenia |
4.1% |
| White Blood Cell Count Decreased |
3.7% |
| Weight Decreased |
3.6% |
| Thrombotic Microangiopathy |
3.1% |
| Pancytopenia |
3.1% |
| Renal Failure Acute |
2.6% |
| Systemic Lupus Erythematosus |
2.6% |
| Weight Increased |
2.6% |
| Urinary Retention |
2.5% |
| Urinoma |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
16.2% |
| Renal Transplant |
12.7% |
| Prophylaxis Against Graft Versus Host Disease |
9.3% |
| Prophylaxis Against Transplant Rejection |
8.4% |
| Immunosuppression |
8.2% |
| Drug Use For Unknown Indication |
7.1% |
| Bone Marrow Conditioning Regimen |
5.0% |
| Immunosuppressant Drug Therapy |
4.4% |
| Prophylaxis |
4.2% |
| Infection Prophylaxis |
3.4% |
| Stem Cell Transplant |
3.3% |
| Hypertension |
3.1% |
| Heart Transplant |
2.5% |
| Liver Transplant |
2.2% |
| Antifungal Prophylaxis |
2.1% |
| Graft Versus Host Disease |
1.8% |
| Lung Transplant |
1.7% |
| Antiviral Prophylaxis |
1.5% |
| Acute Graft Versus Host Disease |
1.4% |
| Acute Myeloid Leukaemia |
1.4% |
|
| Transplant Rejection |
10.8% |
| Vomiting |
9.0% |
| Kidney Transplant Rejection |
7.0% |
| Thrombotic Microangiopathy |
6.6% |
| Sepsis |
6.4% |
| Pyrexia |
5.6% |
| Renal Impairment |
4.9% |
| Renal Failure Acute |
4.8% |
| Renal Failure |
4.5% |
| Drug Ineffective |
4.5% |
| Rhabdomyolysis |
4.1% |
| Respiratory Failure |
4.0% |
| Acute Graft Versus Host Disease |
3.8% |
| Death |
3.8% |
| Thrombocytopenia |
3.8% |
| White Blood Cell Count Decreased |
3.8% |
| Pneumonia |
3.3% |
| Transplant Failure |
3.3% |
| Infection |
3.1% |
| Weight Increased |
3.1% |
|
| Interacting |
| Renal Transplant |
19.0% |
| Immunosuppression |
14.5% |
| Immunosuppressant Drug Therapy |
9.5% |
| Hiv Infection |
7.7% |
| Prophylaxis Against Transplant Rejection |
6.8% |
| Antiretroviral Therapy |
5.4% |
| Pyrexia |
5.4% |
| Analgesic Therapy |
4.1% |
| Bone Marrow Conditioning Regimen |
4.1% |
| Infection Prophylaxis |
4.1% |
| Liver Transplant |
3.2% |
| Dyslipidaemia |
2.3% |
| Prophylaxis |
2.3% |
| Pulmonary Tuberculosis |
2.3% |
| Convulsion |
1.8% |
| Hypertension |
1.8% |
| Lower Respiratory Tract Infection |
1.8% |
| Blood Triglycerides Increased |
1.4% |
| Bone Marrow Transplant |
1.4% |
| Drug Use For Unknown Indication |
1.4% |
|
| Transplant Rejection |
29.4% |
| Drug Interaction |
7.8% |
| Pyrexia |
7.8% |
| Renal Impairment |
7.8% |
| Acute Graft Versus Host Disease In Intestine |
5.9% |
| Drug Level Decreased |
5.9% |
| Febrile Neutropenia |
3.9% |
| Haemoglobin Decreased |
3.9% |
| Myeloid Maturation Arrest |
3.9% |
| Stomatitis |
3.9% |
| Grand Mal Convulsion |
2.0% |
| Hepatic Function Abnormal |
2.0% |
| Liver Disorder |
2.0% |
| Neutropenia |
2.0% |
| Oliguria |
2.0% |
| Pneumonia Cytomegaloviral |
2.0% |
| Sepsis |
2.0% |
| Therapeutic Response Decreased |
2.0% |
| Treatment Noncompliance |
2.0% |
| Tremor |
2.0% |
|
